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ambulatory setting [2] (cost base year 2005). As only costs were considered, no dis-
counting was applied. RESULTS: In the ﬁrst year after initiating a BOT, costs per 
patient are slightly higher (a3.25) in GLA- than NPH-based regimens. From year two 
GLA regimens show an increasing cost advantage compared to NPH up to a1,217 
per patient after 10 years. As all patients have changed to ICT at year 10, a longer 
time horizon would not change the ﬁndings. Calculated for an estimated cohort of 
44,366 German T2D covered by the SHI and starting a BOT with GLA (50%) or 
NPH (50%), the total costs over 10 years are a169.7 vs. a223.7 million, respectively. 
CONCLUSIONS: Due to a longer persistence to a basal supported oral therapy in 
T2D, long-term costs of GLA are lower compared to NPH. Therefore, initiating an 
insulin therapy using BOT with GLA leads to potential cost savings of a54 million 
per 10 years for the German SHI. References: [1] Diabetologie und Stoffwechsel 
2009;4:1–6 [2] J Med Econ 2008;11:695–712.
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OBJECTIVES: To compare resource utilization and costs of type-2 diabetic (T2D) 
patients treated with either insulin glargine (GLA) or insulindetemir (DET) in a basal-
bolus regimen. METHODS: LIVE-COM* was a non-interventional study in 138 
primary care centres in Germany (representative sample). 1731 T2D patients with 
statutory health insurance (SHI) status were enrolled when either treated with GLA 
(n  1150) or DET (n  581) in a basal-bolus regimen for at least 6 months prior to 
documentation. Total direct diabetes treatment costs (DTC) derived from antidiabetic 
medications (insulins, oral drugs) and consumables (test strips, lancets, needles) were 
assessed retrospectively over 6 months. RESULTS: Respective patient characteristics 
(mean) for GLA (53% male) and DET (49% male): age: 66/65 years, BMI: 
31.3/32.7 kg/m², HbA1c: 7.5/7.7%, fasting blood glucose: 140/148 mg/dl, onset of 
diabetes 10 yrs ago: 60/59%, start of insulin therapy 5 yrs ago: 62/64%, number 
of diabetic complications (3.0/2.9). Resource use: Compared to DET, GLA patients 
had on average fewer basal insulin injections per day (1.1 vs. 1.3) and required sig-
niﬁcantly less test strips (3.2 vs. 3.6). Mean daily total insulin dose (basal/bolus) was 
signiﬁcantly lower in GLA (27.7/40.3 U) compared to DET (32.1/47.1 U). Reported 
hypoglycemia, hospitalization rates and frequency of physician contacts did not differ 
between groups. Adjusted mean DTC per patient and 6 months were a932 (GLA) vs. 
a1061 (DET); p  0.001. Adjusted mean single costs (GLA vs. DET) were: basal insulin 
a223/246 (p  0.001), bolus insulin a241/289 (p  0.001), oral drugs a37/36 (ns), test 
strips a347/393 (p  0.001), needles a68/80 (p  0.001), lancets a14/16 (ns). CON-
CLUSIONS: Insulin glargine based basal-bolus regimens resulted in annual cost 
savings of a256 per patient compared to DET regimens from the SHI perspective in 
Germany. GLA patients showed better glycemic control under routine care conditions. 
*Long acting Insulin glargine Versus Insulin detemir cost Evaluation COMparison.
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OBJECTIVES: Cost comparison of insulin glargine (IG) versus insulin detemir (ID) in 
a basal-bolus regime with mealtime insulin aspart in type 2 diabetes patients (T2D) 
in Germany. METHODS: Clinical data were taken from a randomised controlled trial 
[1]. IG was administered once daily, ID once or twice daily. Mean daily insulin doses 
(basal :bolus) were 0.59 and 0.32 U/kg for IG and 0.82 and 0.36 U/kg for ID. Gly-                 
caemic control, weight gain, adverse events and risk of hypoglycaemia were similar 
in both groups after 1 year (non inferiority trial) so a cost minimisation analysis was 
undertaken. Costs were calculated from the perspective of the statutory health insur-
ance (SHI) using ofﬁcial 2008 prices. It was assumed that a new needle, lancet and 
test strip were used at the time of each injection. RESULTS: The annual single costs 
per patient for needles were a393 for IG and a449 for ID. The costs of blood glucose 
test strips and lancets were a1125 for IG and a1286 for ID. The overall costs of 
basal-bolus insulin were a1,607 for IG and a2144 for ID. The total annual costs per 
patient was a3126 for IG compared with a3879 for ID, translating into a 19% annual 
cost saving of a753/patient in favour of IG. Sensitivity analyses conﬁrmed the robust-
ness of the results. CONCLUSIONS: IG and ID basal-bolus regimes have comparative 
safety and efﬁcacy outcomes, based on [1], IG however may represent a signiﬁcantly 
more cost saving option for T2D patients in Germany requiring basal-bolus insulin 
analogue therapy with potential cost savings of a753a (19%) compared to ID. REFER-
ENCE: [1] Hollander P et al.. A 52-week, multinational, open-label, parallel-group, 
noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in 
a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. 
Clinical Therapeutics 2008;30:1976–87. Study supported by sanoﬁ-aventis.
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OBJECTIVES: Different insulin regimes may have different efﬁcacy that can be bal-
anced by higher dosing, which means higher costs. Payers are considered to choose 
the more cost effective therapies, and pay less for the same efﬁcacy results. Aim of 
our study was to determine the cost born on payers reimbursing basal analoge insu-
lines. METHODS: We used two studies were designed to achieve the same clinical 
beneﬁt, such as non-inferiority studies. This way the effectiveness will be the same and 
we could focus on costs only. Dose differences were multiplied with actual Hungarian 
costs of insulins RESULTS: We used an article by Rosenstock compared basal ana-
logue insulins in BOT indication and another article by Hollander done on ICT indica-
tion. In the Rosenstock study patients required an average 31 unit higher daily insulin 
dose on detemir than on glargin, to achieve the same clinical effectiveness as there 
was no signiﬁcant difference in terms of HbA1c levels. Using Hugarian drug costs, 
this higher dose with detemir related to an extra cost of HUF 111,887 per year. The 
case was the same with the Hollander study where detemir patients required on 
average 22.5 unit higher daily dose of basal insulins and 4.3 unit more rapid insulin 
on daily average. In the Hungarian health care system this gives an extra cost of HUF 
94,182 on yearly average. CONCLUSIONS: In clinical trials detemir patients requires 
signiﬁcantly more insulin than glargin patients to achieve the same clinical beneﬁt, 
which would result in a signiﬁcantly higher cost in the Hungarian health care 
system.
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OBJECTIVES: Cost comparison of basal insulin analogues detemir (ID) and glargine 
(IG) in combination with oral antidiabetic drugs (basal supported oral therapy; BOT) 
for type-2 diabetes patients in Germany. METHODS: Clinical data were taken from 
a randomised controlled clinical trial (RCT) [1]. IG was administered once daily, ID 
was administered once (45%) or twice daily (55%). After 52 weeks mean daily ID 
dose was 77% higher (0.78 U/kg) than IG dose (0.44 U/kg). Glycemic control, weight 
gain, adverse events and risk of hypoglycemia were comparable after one year (non 
inferiority trial) so a cost minimisation analysis was undertaken. It was assumed that 
a new needle, lancet, and test strip was used at the time of each injection. Annual 
direct treatment costs were estimated from the perspective of the German statutory 
health insurance (SHI). Simulated resources included medication and consumable 
items. Initial and ﬁnal insulin doses and proportion of patients with once/twice daily 
insulin injection were taken from the RCT. Unit costs were taken from ofﬁcial German 
sources. Deterministic- (DTA) and probabilistic sensitivity analyses (PSA) on resource 
use and unit costs were performed. RESULTS: Average annual treatment costs per 
patient (base case) were a941 for IG and a1406 for ID (annual cost saving a464). 
Single costs of consumable items amounted at a380 (IG) and a588 (ID) respectively. 
Sensitivity analyses conﬁrmed the ﬁndings in favour of glargine. PSA results found 
cost savings could be at least a500 with a probability of ^59%. CONCLUSIONS: 
The current model estimated that IG was associated with lower annual treatment costs 
of a464 (33%) compared to the use of IG. REFERENCE: [1] Rosenstock J et al. A 
randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin 
glargine when administered as add-on to glucose-lowering drugs in insulin-naive 
people with type-2 diabetes. Diabetologia 2008;51:408–16.
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OBJECTIVES: To perform a comparative analysis of the costs linked to the treatment 
with Insulin Glargine (IG) or Insulin Detemir (ID) in type 1 diabetes mellitus patients 
from the Mexican private market perspective. METHODS: Clinical data related to 
each treatment derives from a study performed by Pieber and cols. (2008): a 26-week 
open-label, parallel trial, which compares efﬁcacy and safety of IG and ID both in 
combination with insulin aspart. Primary objective in efﬁcacy was HbA1c and 
hypoglycaemias tolerability. HbA1c control is equivalent in the two regimens, while 
the overall risk of hypoglycaemias had no differences in conﬁrmed hypoglycaemias. 
Patients treated with IG required higher bolus dose, but lower basal and total dose of 
insulin. The cost of each treatment regimen was calculated using the unit cost of             
insulin, needles, and blood glucose tests (BGT). Costs calculations referred to year           
2009 and were derived from published tariffs. Sensitivity analysis was performed using 
a Monte Carlo simulation. RESULTS: Overall, patients treated with ID required 
13.5% more total insulin, and 20% more needles and BGT than IG patients. Manage-
ment with IG has lower total costs than ID, which allows savings of a203 per patient 
in the 26 weeks-period. Savings with IG were related to the costs of total insulin, and 
the lower injections required of basal insulin. Sensitivity analysis showed savings from 
a58 to a651 between the percentiles 25 and 95. CONCLUSIONS: For patients with 
